Monitoring Serum Levels of Sorafenib and Its N-Oxide Is Essential for Long-Term Sorafenib Treatment of Patients with Hepatocellular Carcinoma.

@article{Shimada2015MonitoringSL,
  title={Monitoring Serum Levels of Sorafenib and Its N-Oxide Is Essential for Long-Term Sorafenib Treatment of Patients with Hepatocellular Carcinoma.},
  author={Miki Shimada and Hoshimi Okawa and Yasuteru Kondo and Takahiro Maejima and Yuta Kataoka and Kanehiko Hisamichi and Masamitsu Maekawa and Masaki Matsuura and Yuko Jin and Masaru Mori and Hiroyuki Suzuki and Tooru Shimosegawa and Nariyasu Mano},
  journal={The Tohoku journal of experimental medicine},
  year={2015},
  volume={237 3},
  pages={173-82}
}
Sorafenib, an oral multi-kinase inhibitor, is the final therapy prior to palliative care for advanced hepatocellular carcinoma (HCC). However, due to its adverse effects, 20% of patients must discontinue sorafenib within 1 month after first administration. To identify ways to predict the adverse effects and administer the drug for longer periods, we explored the relationship between the duration of sorafenib treatment and the pharmacokinetics of sorafenib and its major metabolite, sorafenib N… CONTINUE READING